Add Yahoo as a preferred source to see more of our stories on Google. Q: I’m dealing with hormonal acne. What’s the best way to clear it up?. “I’m a big fan of topical probiotics for hormonal ...

March 9, 2006 (San Francisco) — The largest and arguably most complex risk-management program ever undertaken by the US Food and Drug Administration is sparking a commensurate measure of controversy — ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." When Grace, 30, a data analyst in North Carolina, got her precious first prescription of isotretinoin, ...

In December 2021, major changes took effect in the iPLEDGE program, the US Food and Drug Administration (FDA)–required safety program for managing the risks of isotretinoin's teratogenicity and ...

Dermatologists have complained that the U.S. Food and Drug Administration's iPledge program is delaying treatment for patients who require the drug Accutane. The program, which was adapted six months ...

The Food and Drug Administration has approved system changes to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) program for isotretinoin products. The system changes will go into effect ...

Please provide your email address to receive an email when new articles are posted on . Pregnancies, abortions and fetal defects associated with isotretinoin exposure continue to be a problem even ...

Please provide your email address to receive an email when new articles are posted on . iPLEDGE requires participating pharmacies to have an identifying number, which jails and prisons do not have.

An FDA advisory committee on Wednesday voted 17-4 (with one abstention) to recommend removing a "lockout period" from a risk evaluation and mitigation strategy (REMS) for isotretinoin prescribing that ...

In a nod toward transgender inclusiveness, the FDA revised the iPLEDGE risk-modification program for isotretinoin by rewording the reproductive categories for patients. Beginning December 13, patients ...

WASHINGTON The Food and Drug Administration announced that Covance, the developer of the iPLEDGE risk management program has fully implemented the program revisions approved by the FDA on Oct. 3. The ...